RxDoctor Payments DataLook up a doctor →

Suraj Verma, MD

Family Medicine · Reno, NVNPI 1134253701

Payments from drug & device makers

$10,519in general payments, 2019–2025

Across 573 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$1K
  • GSK$1K
  • Pfizer$1K
  • Amarin Pharma, Inc.$659
  • Boehringer Ingelheim$512
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$10,37599%
  • Education$1441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,519 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$108,387
Medicare patients
422
Services billed
1,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$33,792
JardianceEmpagliflozin19$33,171
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$29,477
TrulicityDulaglutide20$28,603
Repatha SureclickEvolocumab19$21,154
Breo ElliptaFluticasone/Vilanterol37$20,065
MyrbetriqMirabegron11$7,526
Praluent PenAlirocumab13$6,148
Levothyroxine Sodium221$2,711
Atorvastatin Calcium258$2,644
SynthroidLevothyroxine Sodium46$2,565
Albuterol Sulfate HfaAlbuterol Sulfate102$2,430
Rosuvastatin Calcium158$2,170
Tamsulosin Hcl80$1,629
Lisinopril214$1,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$1,054$49,54259 claims
PfizerEliquis$1,050$33,79232 claims
Boehringer IngelheimJardiance$512$33,17119 claims
Lilly USA, LLCTrulicity$248$28,60320 claims
Astellas Pharma US IncMyrbetriq$503$7,52611 claims
AbbVieSynthroid$1,319$2,56546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 902 family medicine providers in Nevada.

Other family medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →